Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Anti-Hypertensive Drugs Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Anti-Hypertensive Drugs Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Diuretics
1.3.3 Angiotensin Converting Enzyme (ACE) Inhibitors
1.3.4 Angiotensin Receptor Blockers (ARBs)
1.3.5 Calcium Channel Blockers
1.3.6 Beta Blockers
1.3.7 Alpha Blockers
1.3.8 Vasodilators
1.3.9 Renin Inhibitors
1.4 Market Segment by Application
1.4.1 Global Anti-Hypertensive Drugs Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Anti-Hypertensive Drugs Revenue (2015-2026)
2.1.1 Global Anti-Hypertensive Drugs Revenue (2015-2026)
2.1.2 Global Anti-Hypertensive Drugs Sales (2015-2026)
2.2 Anti-Hypertensive Drugs Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Anti-Hypertensive Drugs Sales by Regions (2015-2020)
2.2.2 Global Anti-Hypertensive Drugs Revenue by Regions (2015-2020)
2.3 Global Top Anti-Hypertensive Drugs Regions (Countries) Ranking by Market Size
2.4 Anti-Hypertensive Drugs Industry Trends
2.4.1 Anti-Hypertensive Drugs Market Top Trends
2.4.2 Market Drivers
2.4.3 Anti-Hypertensive Drugs Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Anti-Hypertensive Drugs Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Anti-Hypertensive Drugs Manufacturers by Sales (2015-2020)
3.1.1 Global Anti-Hypertensive Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Anti-Hypertensive Drugs Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Anti-Hypertensive Drugs Sales in 2019
3.2 Global Top Manufacturers Anti-Hypertensive Drugs by Revenue
3.2.1 Global Anti-Hypertensive Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Anti-Hypertensive Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-Hypertensive Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Hypertensive Drugs as of 2019)
3.4 Global Anti-Hypertensive Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Anti-Hypertensive Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Anti-Hypertensive Drugs Market
3.7 Key Manufacturers Anti-Hypertensive Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Anti-Hypertensive Drugs Historic Market Review by Type (2015-2020)
4.1.2 Global Anti-Hypertensive Drugs Sales Market Share by Type (2015-2020)
4.1.3 Global Anti-Hypertensive Drugs Revenue Market Share by Type (2015-2020)
4.1.4 Anti-Hypertensive Drugs Price by Type (2015-2020)
4.1 Global Anti-Hypertensive Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Anti-Hypertensive Drugs Sales Forecast by Type (2021-2026)
4.2.3 Global Anti-Hypertensive Drugs Revenue Forecast by Type (2021-2026)
4.2.4 Anti-Hypertensive Drugs Price Forecast by Type (2021-2026)
5 Global Anti-Hypertensive Drugs Market Size by Application
5.1 Global Anti-Hypertensive Drugs Historic Market Review by Application (2015-2020)
5.1.2 Global Anti-Hypertensive Drugs Sales Market Share by Application (2015-2020)
5.1.3 Global Anti-Hypertensive Drugs Revenue Market Share by Application (2015-2020)
5.1.4 Anti-Hypertensive Drugs Price by Application (2015-2020)
5.2 Global Anti-Hypertensive Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Anti-Hypertensive Drugs Sales Forecast by Application (2021-2026)
5.2.3 Global Anti-Hypertensive Drugs Revenue Forecast by Application (2021-2026)
5.2.4 Anti-Hypertensive Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anti-Hypertensive Drugs Breakdown Data by Company
6.2 North America Anti-Hypertensive Drugs Breakdown Data by Type
6.3 North America Anti-Hypertensive Drugs Breakdown Data by Application
6.4 North America Anti-Hypertensive Drugs Breakdown Data by Countries
6.4.1 North America Anti-Hypertensive Drugs Sales by Countries
6.4.2 North America Anti-Hypertensive Drugs Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Anti-Hypertensive Drugs Breakdown Data by Company
7.2 Europe Anti-Hypertensive Drugs Breakdown Data by Type
7.3 Europe Anti-Hypertensive Drugs Breakdown Data by Application
7.4 Europe Anti-Hypertensive Drugs Breakdown Data by Countries
7.4.1 Europe Anti-Hypertensive Drugs Sales by Countries
7.4.2 Europe Anti-Hypertensive Drugs Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Anti-Hypertensive Drugs Breakdown Data by Company
8.2 Asia Pacific Anti-Hypertensive Drugs Breakdown Data by Type
8.3 Asia Pacific Anti-Hypertensive Drugs Breakdown Data by Application
8.4 Asia Pacific Anti-Hypertensive Drugs Breakdown Data by Regions
8.4.1 Asia Pacific Anti-Hypertensive Drugs Sales by Regions
8.4.2 Asia Pacific Anti-Hypertensive Drugs Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Anti-Hypertensive Drugs Breakdown Data by Company
9.2 Latin America Anti-Hypertensive Drugs Breakdown Data by Type
9.3 Latin America Anti-Hypertensive Drugs Breakdown Data by Application
9.4 Latin America Anti-Hypertensive Drugs Breakdown Data by Countries
9.4.1 Latin America Anti-Hypertensive Drugs Sales by Countries
9.4.2 Latin America Anti-Hypertensive Drugs Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Anti-Hypertensive Drugs Breakdown Data by Type
10.2 Middle East and Africa Anti-Hypertensive Drugs Breakdown Data by Application
10.3 Middle East and Africa Anti-Hypertensive Drugs Breakdown Data by Countries
10.3.1 Middle East and Africa Anti-Hypertensive Drugs Sales by Countries
10.3.2 Middle East and Africa Anti-Hypertensive Drugs Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Novartis Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Novartis Anti-Hypertensive Drugs Products and Services
11.1.5 Novartis SWOT Analysis
11.1.6 Novartis Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Pfizer Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Pfizer Anti-Hypertensive Drugs Products and Services
11.2.5 Pfizer SWOT Analysis
11.2.6 Pfizer Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Johnson & Johnson Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Johnson & Johnson Anti-Hypertensive Drugs Products and Services
11.3.5 Johnson & Johnson SWOT Analysis
11.3.6 Johnson & Johnson Recent Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Sanofi Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Sanofi Anti-Hypertensive Drugs Products and Services
11.4.5 Sanofi SWOT Analysis
11.4.6 Sanofi Recent Developments
11.5 Lupin
11.5.1 Lupin Corporation Information
11.5.2 Lupin Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Lupin Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Lupin Anti-Hypertensive Drugs Products and Services
11.5.5 Lupin SWOT Analysis
11.5.6 Lupin Recent Developments
11.6 Ranbaxy Laboratories
11.6.1 Ranbaxy Laboratories Corporation Information
11.6.2 Ranbaxy Laboratories Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Ranbaxy Laboratories Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Ranbaxy Laboratories Anti-Hypertensive Drugs Products and Services
11.6.5 Ranbaxy Laboratories SWOT Analysis
11.6.6 Ranbaxy Laboratories Recent Developments
11.7 Merck
11.7.1 Merck Corporation Information
11.7.2 Merck Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Merck Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Merck Anti-Hypertensive Drugs Products and Services
11.7.5 Merck SWOT Analysis
11.7.6 Merck Recent Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Corporation Information
11.8.2 AstraZeneca Business Overview and Total Revenue (2019 VS 2018)
11.8.3 AstraZeneca Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 AstraZeneca Anti-Hypertensive Drugs Products and Services
11.8.5 AstraZeneca SWOT Analysis
11.8.6 AstraZeneca Recent Developments
11.9 Daiichi Sankyo Company Limited
11.9.1 Daiichi Sankyo Company Limited Corporation Information
11.9.2 Daiichi Sankyo Company Limited Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Daiichi Sankyo Company Limited Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Daiichi Sankyo Company Limited Anti-Hypertensive Drugs Products and Services
11.9.5 Daiichi Sankyo Company Limited SWOT Analysis
11.9.6 Daiichi Sankyo Company Limited Recent Developments
11.10 Takeda Pharmaceutical
11.10.1 Takeda Pharmaceutical Corporation Information
11.10.2 Takeda Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Takeda Pharmaceutical Anti-Hypertensive Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Takeda Pharmaceutical Anti-Hypertensive Drugs Products and Services
11.10.5 Takeda Pharmaceutical SWOT Analysis
11.10.6 Takeda Pharmaceutical Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Anti-Hypertensive Drugs Sales Channels
12.2.2 Anti-Hypertensive Drugs Distributors
12.3 Anti-Hypertensive Drugs Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Anti-Hypertensive Drugs Sales Forecast (2021-2026)
13.1.1 Global Anti-Hypertensive Drugs Sales Forecast by Regions (2021-2026)
13.1.2 Global Anti-Hypertensive Drugs Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Anti-Hypertensive Drugs Sales Forecast (2021-2026)
13.2.2 North America Anti-Hypertensive Drugs Revenue Forecast (2021-2026)
13.2.3 North America Anti-Hypertensive Drugs Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Anti-Hypertensive Drugs Sales Forecast (2021-2026)
13.3.2 Europe Anti-Hypertensive Drugs Revenue Forecast (2021-2026)
13.3.3 Europe Anti-Hypertensive Drugs Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Anti-Hypertensive Drugs Sales Forecast (2021-2026)
13.4.2 Asia Pacific Anti-Hypertensive Drugs Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Anti-Hypertensive Drugs Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Anti-Hypertensive Drugs Sales Forecast (2021-2026)
13.5.2 Latin America Anti-Hypertensive Drugs Revenue Forecast (2021-2026)
13.5.3 Latin America Anti-Hypertensive Drugs Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Anti-Hypertensive Drugs Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Anti-Hypertensive Drugs Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Anti-Hypertensive Drugs Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Novartis、Pfizer、Johnson & Johnson、Sanofi、Lupin、Ranbaxy Laboratories、Merck、AstraZeneca、Daiichi Sankyo Company Limited、Takeda Pharmaceutical
【免責事項】
https://www.globalresearch.jp/disclaimer